Healthcare -
Biotechnology - NASDAQ - US
$ 3.19
9.25 %
$ 720 M
Market Cap
-3.62
P/E
1. INTRINSIC VALUE
Balance Sheet
Sana Biotechnology, Inc.
| Current Assets | 161 M |
| Cash & Short-Term Investments | 152 M |
| Receivables | 0 |
| Other Current Assets | 8.31 M |
| Non-Current Assets | 340 M |
| Long-Term Investments | 0 |
| PP&E | 135 M |
| Other Non-Current Assets | 205 M |
| Current Liabilities | 45.4 M |
| Accounts Payable | 5.21 M |
| Short-Term Debt | 12.5 M |
| Other Current Liabilities | 27.7 M |
| Non-Current Liabilities | 205 M |
| Long-Term Debt | 81.7 M |
| Other Non-Current Liabilities | 123 M |
EFFICIENCY
Earnings Waterfall
Sana Biotechnology, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 282 M |
| Operating Income | -273 M |
| Other Expenses | -5.96 M |
| Net Income | -267 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sana Biotechnology, Inc.
| Net Income | -267 M |
| Depreciation & Amortization | 17.4 M |
| Capital Expenditures | -33.4 M |
| Stock-Based Compensation | 37.7 M |
| Change in Working Capital | -1.18 M |
| Others | -12.8 M |
| Free Cash Flow | -257 M |
Wall Street Analysts Price Targets
Sana Biotechnology, Inc.
Wall Street analysts predict an average 1-year price target for SANA of $8 , with forecasts ranging from
a
low of
$8 to a high of $8 .
SANA Lowest Price Target
Wall Street Target
8 USD
150.78%
SANA Average Price Target
Wall Street Target
8 USD
150.78%
SANA Highest Price Target
Wall Street Target
8 USD
150.78%
4. DIVIDEND
ANALYSIS
SANA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Sana Biotechnology, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.89 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.2 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression
globenewswire.com
- 2 weeks ago
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
globenewswire.com
- 4 weeks ago
Sana Biotechnology to Present at June 2025 Investor Conferences
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.
globenewswire.com
- 1 month ago
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149443&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 month ago
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
globenewswire.com
- 1 month ago
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149393&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 month ago
SANA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
accessnewswire.com
- 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
prnewswire.com
- 1 month ago
Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149338&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 month ago
SANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
accessnewswire.com
- 1 month ago
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK , May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
prnewswire.com
- 1 month ago
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors - Lead Plaintiff Deadline May 20, 2025
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149279&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 1 month ago
8. Profile
Summary
Sana Biotechnology, Inc. SANA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 720 M
Dividend Yield
0.00%
Description
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Contact
188 East Blaine Street, Seattle, WA, 98102
https://www.sana.com
IPO
Date
Feb. 4, 2021
Employees
194
Officers
Dr. Dhavalkumar D. Patel M.D., Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. Snehal Patel
Senior Vice President & Chief Technical Officer
Mr. Bernard J. Cassidy J.D.
Executive Vice President, General Counsel & Corporate Secretary
Ms. Susan Wyrick
Acting Chief Financial Officer, Treasurer, Principal Accounting Officer and Senior Vice President of Finance & Accounting
Mr. John Gerecitano M.D., Ph.D.
Head of Oncology Research & Development
Dr. Sonja Schrepfer M.D., Ph.D.
Senior Vice President & Head of Hypoimmune Platform
Dr. Gary Meininger M.D.
Chief Medical Officer
Dr. Steven D. Harr M.D.
President, Chief Executive Officer & Director
Dr. Yuko Soneoka J.D., Ph.D.
Head of Intellectual Property